Neurology Central

hsa_circRNA_103636: potential novel diagnostic and therapeutic biomarker in Major depressive disorder

Currently, more than 800 million people worldwide suffer from major depressive disorder (MDD). Due to the high incidence, early onset, chronic course, unnatural death and impaired social function and cognitive ability caused by this condition [1], depression will become the second leading contributor to disease burden by the year 2020 [2]. MDD is a heterogeneous illness, and there are currently no effective methods to objectively assess the severity, endophenotypes, or prognosis of this disease. Additionally, its occurrence and development are influenced by social environmental factors. Thus, one effective measure to reduce the burden on society is to identify potential biomarkers to allow for earlier diagnosis and intervention.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.